1361551-13-4

Upstream product

• 18162-48-6 tert-butyldimethylsilyl chloride 
• 1436866-91-9 C₂₁H₃₄O₆SSi 
• 501015-40-3 (2S,3S)-(+)-toluene-4-sulfonic acid 3-hydroxy-2-methylhex-5-enyl ester 
• 183293-41-6 (S)-O-p-toluenesulfonyl-3-hydroxy-2-methylpropanal 
• 98-59-9 p-toluenesulfonyl chloride 
• 84341-89-9 (2S)-(+)-2-methyl-3-(toluene-4-sulfonyloxy)propionic acid methyl ester 

Relevant academic research and scientific papers

Structural variants of mycolactones for use in modulating inflammation, immunity and pain

The present invention is related to variants of mycolactones of formula (I), processes for the preparation thereof, pharmaceutical compositions thereof and their use in modulating inflammation, immunity and pain. ???????? Y-O-W?????(I) wherein Y and W are as defined in claim 1.

STRUCTURAL VARIANTS OF MYCOLACTONES FOR USE IN MODULATING INFLAMMATION, IMMUNITY AND PAIN

The present invention is related to variants of mycolactones of formula (I), processes for the preparation thereof, pharmaceutical compositions thereof and their use in modulating inflammation, immunity and pain. Y-O-W (I), wherein Y and W are as defined in claim 1.

A diverted total synthesis of mycolactone analogues: An insight into buruli ulcer toxins

Mycolactones are complex macrolides responsible for a severe necrotizing skin disease called Buruli ulcer. Deciphering their functional interactions is of fundamental importance for the understanding, and ultimately, the control of this devastating mycobacterial infection. We report herein a diverted total synthesis approach of mycolactones analogues and provide the first insights into their structure-activity relationship based on cytopathic assays on L929 fibroblasts. The lowest concentration inducing a cytopathic effect was determined for selected analogues, allowing a clear picture to emerge by comparison with the natural toxins.